RLMD

Relmada Therapeutics
$5.20
+$0.02 (+0.39%)Jul 27, 2026
4.5NeutralMoatMint rating

MoatMint rates Relmada Therapeutics (RLMD) 4.5 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 0.3 out of 10.

Key metrics

The numbers that frame RLMD today
Market cap
$545.43M
P/E (TTM)
-9.3
EV / FCF
-12.5
ROIC
-73.7%
Div yield
0%
Debt / equity
0.0
52wk Low
$0.55
52wk High
$8.00

RLMD stock rating

How RLMD scores on quality, value, growth, momentum and financial health
4.5out of 10
Neutral overallHealthy business, expensive priceTop 55% of ~5,000 US stocks
QualityPoor0.3/10
GrowthGreat9.3/10
MomentumGreat9.9/10
ValueFair2.4/10
Financial HealthNeutral4.3/10

Growth

Revenue and earnings trend for RLMD
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about RLMD
Is Relmada Therapeutics a good buy?
Hold. Relmada Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks excellent, which supports the long-term business case. We think Relmada Therapeutics is selling at a very high price.
What is the market capitalization of RLMD?
Relmada Therapeutics's market capitalization is $545.43M.
What is the P/E ratio for RLMD stock?
Relmada Therapeutics's current P/E ratio is -9.3.
What is the 52-week high for RLMD stock?
The 52-week high for Relmada Therapeutics is $8.00. The current close of $5.20 is 35% below that high.
What is the 52-week low for RLMD stock?
The 52-week low for Relmada Therapeutics is $0.55. The current close of $5.20 is 845.5% above that low.
Does RLMD stock pay dividends?
Relmada Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for RLMD?
Relmada Therapeutics's Debt / Equity ratio is 0.